Immunofluorescence of human PECAM-1
(A-B), mouse PECAM-1
(C-D) and mouse red blood cells (E-F) for T (left column) and ET models (right column), at 7 days.
is required for transendothelial migration of leukocytes.
Most IHC studies have shown that KS lesional cells express endothelial antigens based upon their immunoreactivity for Ulex europaeus agglutinin-1 (UEA-1), thrombomodulin, factor VIII-related antigen (von Willebrand factor), CD31 (also called PECAM-1
for platelet endothelial cell adhesion molecule) (Figures 6A,B), and CD34 [81,82].
senior scientist at the California Pacific Medical Center Research Institute in collaboration with four other laboratories has shown that a monoclonal antibody targeting a protein called PECAM-1
is effective against this now invariably lethal stage of cancer in mice.
(CD31) is expressed on proliferating endothelial cells, stromal spindle-shaped cells, and dermal dendrocytes in Kaposi's sarcoma.
Platelet-endothelial cell adhesion molecule-1 (PECAM-1
)deficient mice demonstrate a transient and cytokine-specific role for PECAM-1
in leukocyte migration through the perivascular basement membrane.